Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.42 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.42 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2887195 | 0.83 | L3MBTL1 (0.62) | L3MBTL1PTGDR2KDM4ETRPM8ALDH1A1 | |
| SCHEMBL2481891 | 0.81 | L3MBTL1 (0.49) | L3MBTL1HPGDSKDM4ETRPM8ALDH1A1 | |
| SCHEMBL2485550 | 0.81 | L3MBTL1 (0.51) | L3MBTL1HPGDSPTGDR2KDM4EPOLB | |
| SCHEMBL12030404 | 0.81 | L3MBTL1 (0.55) | L3MBTL1PTGDR2KDM4EPOLBTRPM8 | |
| SCHEMBL13345951 | 0.79 | L3MBTL1 (0.57) | L3MBTL1TRPM8ALDH1A1CDC7DBF4 | |
| SCHEMBL27931296 | 0.73 | L3MBTL1 (0.60) | L3MBTL1TRPM8ALDH1A1LMNACDC7 | |
| SCHEMBL16312760 | 0.73 | SMN1; SMN2 (0.66) | L3MBTL1KDM4ETRPM8ALDH1A1LMNA | |
| SCHEMBL2427248 | 0.72 | GRM6 (0.47) | L3MBTL1HPGDSKDM4EPOLBTRPM8 | |
| SCHEMBL5197191 | 0.72 | CDC7 (0.52) | L3MBTL1HPGDSTRPM8ALDH1A1CDC7 | |
| SCHEMBL12049697 | 0.71 | CDC7 (0.64) | L3MBTL1KDM4ETRPM8ALDH1A1CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376502-B1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-06-17 | — | — | EP | disclosed |
| EP-2376502-B1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-06-17 | — | — | EP | disclosed |
| US-8492401-B2 | Thiazolopyridine sirtuin modulating compounds | GLAXOSMITHKLINE LLC (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492401-B2 | Thiazolopyridine sirtuin modulating compounds | GLAXOSMITHKLINE LLC (US) | 2013-07-23 | — | — | US | disclosed |
| US-20130085155-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085155-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS (US) | 2013-04-04 | — | — | US | disclosed |
| US-8343997-B2 | Thiazolopyridine sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20110306609-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC., | 2011-12-15 | — | — | US | disclosed |
| EP-2376502-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | Sirtris Pharmaceuticals, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071853-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085155-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | L3MBTL1 4230/4885HPGDS 1023/4885PTGDR2 2563/4885 |
| US-20110306609-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | L3MBTL1 4230/4885HPGDS 1023/4885PTGDR2 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.